Generic Reglan makers released from Tardive Dyskinesia lawsuit
Wyeth, Inc. and Schwarz Pharma Inc. have been dismissed from a lawsuit filed in Texas involving the drug company’s Reglan (metoclopramide), a medicine used to treat gastrointestinal conditions. The lawsuit alleged that the drug caused the plaintiff to develop a severe movement disorder known as Tardive Dyskinesia. However, the case will proceed against Activis-Elizabeth, L.L.C., makers of a generic version of metoclopramide that the plaintiff was taking.
![[ Beasley Allen Law Firm Logo ]](http://www.reglan-lawyer.net/wp-content/themes/system-unity/images/logo.png)

A new study has found that quality improvement intervention initiatives such as ongoing education and automated feedback reports of medication usage among low birth weight babies in neonatal intensive care units (NICU) can significantly reduce use of medications, some of which carry serious adverse effects.
A combination of aspirin and the anti-nausea medication
For nine years, Valerie (not her real name) was prescribed and took
A New Jersey judge is calling for a statewide consolidation of all lawsuits filed against the makers of the heartburn medication
Mederi Therapeutics Inc. is launching an innovative new radiofrequency device for the treatment of gastroesophageal reflux disease, also known as GERD. Mederi’s Stretta is a balloon catheter with a needle that delivers radiofrequency energy. The system is inserted into the esophagogastric junction, or the sphincter controlling the entrance of food into the stomach, and prevents stomach acids from backing up into the esophagus. The radiofrequency waves work to restore the function of the valve separating the esophagus from the stomach.
The new health care reform bill gives senior citizens a rebate to purchase prescription medications; however, increasing availability of drugs for seniors may cause safety concerns, especially when it comes to generic versions of medication, according to a
Salix Pharmaceuticals stock rose 5 percent last week despite news that the company received a warning letter from the Food and Drug Administration (FDA) urging the company to clarify information about its new orally dissolving heartburn treatment, Metozolv ODT, according to